Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765812 · ClinicalTrials.gov registry record · Phase 1
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
A Phase 1 study of Astrocytoma, Grade III and Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, sponsored by Debiopharm International.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 17
- Study locations
NCT05765812: Recruiting Phase 1 study of Astrocytoma, Grade III and Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, sponsored by Debiopharm International.
NCT05765812 is a Phase 1 study of Astrocytoma, Grade III and Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype that is actively recruiting participants, run by Debiopharm International. The registered enrollment target is 116 participants, below the 230-participant average among 4 other Astrocytoma, Grade III trials with a reported enrollment target (50% lower). The trial reports 17 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05765812, a Phase 1 study of Astrocytoma, Grade III and Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, is actively recruiting participants, sponsored by Debiopharm International.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 17
- Study locations
Study Summary
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to characterize the safety and tolerability of these combinations in adult participants with glioblastoma (GBM). Arm B which was previously added to the protocol, has been permanently halted per the safety monitoring committees' decision on the safety findings of this arm. The primary purpose of Phase 1 (Dose expansion) of the study is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development. The Phase 2 will start once the RD Phase 1 has been defined. The primary objective of Phase 2 is to assess the efficacy of Debio 0123 at the RD for further development in combination with TMZ, compared to the standard of care (SOC) in adult participants with GBM.
Conditions Studied
Interventions
- DRUG Temozolomide
- RADIATION Radiotherapy
- DRUG Debio 0123
Study Locations (17)
Other
- Hospital Universitario Vall d'Hebron - Barcelona
- Hospital Universitario Donostia - Donostia / San Sebastian
- Clinica Universidad de Navarra (CUN) - Madrid
- South Texas Accelerated Research Therapeutics (START) - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Clinica Universidad de Navarra (CUN) - Pamplona
- Hospital Universitario Donostia - San Sebastián
- Hospital Clinico Universitario de Valencia - Valencia
- Universitaetsspital Zuerich - Zurich
Texas
- Baylor Scott & White Research Institute - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics (START) - San Antonio
New York
- New York University Langone Medical Center - New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
Illinois
- Northwestern Memorial Hospital - Chicago
Utah
- Huntsman Cancer Institute - Salt Lake City
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2028-09 |
| Phase | Phase 1 |
What NCT05765812 shows while recruiting
NCT05765812 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 230-participant average among 4 other Astrocytoma, Grade III trials with a reported enrollment target (50% lower).
The record links to 2 conditions, with Astrocytoma, Grade III appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT05765812 lists 17 locations in 6 states (Other, Texas, New York).
Frequently Asked Questions
What is clinical trial NCT05765812 about?
NCT05765812 is a clinical study titled "A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma". The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to characterize the safety and tolerability of these combinations in adul...
What is the current status of trial NCT05765812?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2023-05-15. Estimated completion is 2028-09.
What conditions does trial NCT05765812 study?
This clinical trial studies the following conditions: Astrocytoma, Grade III, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype.
What interventions are being tested in trial NCT05765812?
The interventions under investigation include: Temozolomide (DRUG), Radiotherapy (RADIATION), Debio 0123 (DRUG).
Who is sponsoring clinical trial NCT05765812?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05765812 being conducted?
This trial has 17 study locations across Illinois, New York, Texas, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Astrocytoma, Grade III
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
RECRUITING · Phase 1
-
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
ACTIVE NOT RECRUITING · Phase 1
-
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RECRUITING
-
Study of Olutasidenib and Temozolomide in HGG
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI